196 related articles for article (PubMed ID: 36849497)
1. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G
Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Jodele S; Licht C; Goebel J; Dixon BP; Zhang K; Sivakumaran TA; Davies SM; Pluthero FG; Lu L; Laskin BL
Blood; 2013 Sep; 122(12):2003-7. PubMed ID: 23814021
[TBL] [Abstract][Full Text] [Related]
3. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition.
Catanese L; Link K; Rupprecht H
BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151
[TBL] [Abstract][Full Text] [Related]
4. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.
Gavriilaki E; Dalampira D; Theodorakakou F; Liacos CI; Kanellias N; Eleutherakis-Papaiakovou E; Terpos E; Gavriatopoulou M; Verrou E; Triantafyllou T; Sevastoudi A; Koravou EE; Touloumenidou T; Varelas C; Papalexandri A; Sakellari I; Dimopoulos MA; Kastritis E; Katodritou E
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743426
[TBL] [Abstract][Full Text] [Related]
5. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma.
Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M
BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512
[TBL] [Abstract][Full Text] [Related]
6. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy.
Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M
Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083
[TBL] [Abstract][Full Text] [Related]
7. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
[TBL] [Abstract][Full Text] [Related]
8. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature.
Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717
[TBL] [Abstract][Full Text] [Related]
11. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy.
Fang W; Sun W; Fang W; Zhao S; Wang C
Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange.
Sullivan MR; Danilov AV; Lansigan F; Dunbar NM
J Clin Apher; 2015 Oct; 30(5):308-10. PubMed ID: 25413611
[TBL] [Abstract][Full Text] [Related]
13. A review of thrombotic microangiopathies in multiple myeloma.
Portuguese AJ; Gleber C; Passero FC; Lipe B
Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728
[TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.
Jindal N; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Nada R; Sethi J; Ahluwalia J; Malhotra P
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):426-431. PubMed ID: 32735793
[TBL] [Abstract][Full Text] [Related]
15. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.
Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K
Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib: A cause of drug associated thrombotic microangiopathy.
Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J
Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313
[TBL] [Abstract][Full Text] [Related]
18. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
Sridharan M; Go RS; Willrich MAV
J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature.
Saleem M; Shaikh S; Hu Z; Pozzi N; Java A
Front Immunol; 2022; 13():909503. PubMed ID: 35720299
[TBL] [Abstract][Full Text] [Related]
20. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.
Trojnar E; Józsi M; Szabó Z; Réti M; Farkas P; Kelen K; Reusz GS; Szabó AJ; Garam N; Mikes B; Sinkovits G; Mező B; Csuka D; Prohászka Z
Front Immunol; 2019; 10():240. PubMed ID: 30858847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
